Lv5
830 积分 2025-03-26 加入
From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy
25天前
已完结
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
25天前
已完结
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
25天前
已完结
Vessel co-option and resistance to anti-angiogenic therapy
25天前
已完结
Expression of EWS-ETS Fusions in NIH3T3 Cells Reveals Significant Differences to Ewing’s Sarcoma
25天前
已完结
Ceramide mediates radiation-induced death of endothelium
25天前
已完结
Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
25天前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
25天前
已完结
Fruquintinib: First Global Approval
25天前
已完结
Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights
25天前
已完结
皖公网安备34019202002308